References
- Siegel RL, Miller KD, Wagle NS,Jemal A. Cancer statistics, 2023. CA Cancer J Clin 2023; 73: 17-48. doi: 10.3322/caac.21763
- Alhashimi RAH, Mirzaei AR, Alsaedy HK. Molecular and clinical analysis of genes involved in gastric cancer. Cell Mol Biomed Rep 2021; 1: 138-46. doi: 10.55705/cmbr.2021.355860.1056
- Keller DS, Berho M, Perez RO, Wexner SD,Chand M, The multidisciplinary management of rectal cancer. Nat Rev Gastroenterol Hepatol 2020; 17: 414-29. doi: 10.1038/s41575-020-0275-y
- Li X, Mohammadi MR. Combined diagnostic efficacy of red blood cell distribution width (RDW), prealbumin (PA), platelet-to-lymphocyte ratio (PLR), and carcinoembryonic antigen (CEA) as biomarkers in the diagnosis of colorectal cancer. Cell Mol Biomed Rep 2023; 3: 98-106. doi: 10.55705/cmbr.2023.374804.1088
- Dayde D, Tanaka I, Jain R, Tai MC, Taguchi A. Predictive and prognostic molecular biomarkers for response to neoadjuvant chemoradiation in rectal cancer. Int J Mol Sci 2017; 18: 573. doi: 10.3390/ijms18030573
- Roy S. Membrane-associated RING ubiquitin ligase RNF-121 and advancement of cancer. Cel Mol Biomed Rep 2025; 5: 80-90. doi: 10.55705/cmbr.2025.469983.1276
- Arina A, Gutiontov SI, Weichselbaum RR. Radiotherapy and immunotherapy for cancer: From “Systemic” to “Multisite”. Clin Cancer Res 2020; 26: 277782. doi: 10.1158/1078-0432.Ccr-19-2034
- Chalabi M, Fanchi LF, Dijkstra KK, Van den Berg JG, Aalbers AG, Sikorska K, et al. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. Nat Med 2020; 26: 566-76. doi: 10.1038/s41591-020-0805-8
- Cercek A, Lumish M, Sinopoli J, Weiss J, Shia J, Lamendola-Essel M, et al. PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer. N Engl J Med 2022; 386: 2363-76. doi: 10.1056/NEJMoa2201445
- Bando H, Tsukada Y, Inamori K, Togashi Y, Koyama S, Kotani D, et al. Preoperative chemoradiotherapy plus nivolumab before surgery in patients with microsatellite stable and microsatellite instability-high locally advanced rectal cancer. Clin Cancer Res 2022; 28: 1136-46. doi: 10.1158/1078-0432. Ccr-21-3213
- Lin Z, Cai M, Zhang P, Li G, Liu T, Li X, et al. Phase II, single-arm trial of preoperative short-course radiotherapy followed by chemotherapy and camrelizumab in locally advanced rectal cancer. J Immunother Cancer 2021; 9: e003554. doi: 10.1136/jitc-2021-003554
- Barrett T, Wilhite SE, Ledoux P, Evangelista C, Kim IF, Tomashevsky M, et al. NCBI GEO: archive for functional genomics data sets - update. Nucleic Acids Res 2013; 41: D991-5. doi: 10.1093/nar/gks1193
- GTEx Consortium. The Genotype-Tissue Expression (GTEx) project. Nat Genet 2013; 45: 580-5. doi: 10.1038/ng.2653
- Bolstad BM, Irizarry RA, Astrand M,Speed TP. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 2003; 19: 185-93. doi: 10.1093/bioinformatics/19.2.185
- Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res 2015; 43: e47. doi: 10.1093/nar/gkv007
- Wickham H. ggplot2. Elegant graphics for data analysis. New York: Springer-Verlag; 2016.
- Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS 2012; 16: 284-7. doi: 10.1089/omi.2011.0118
- Yu G, Gao CH. Package ‘enrichplot’. Visualization of Functional Enrichment Result; 2024. [internet]. [cited 2024 Nov 22]. Available at: https://www. bioconductor.org/packages/devel/bioc/manuals/enrichplot/man/enrich-plot.pdf
- Szklarczyk D, Kirsch R, Koutrouli M, Nastou K, Mehryary F, Hachilif R, et al. The STRING database in 2023: protein-protein association networks and functional enrichment analyses for any sequenced genome of interest. Nucleic Acids Res 2023; 51: D638-46. doi: 10.1093/nar/gkac1000
- Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 2003; 13: 2498-504. doi: 10.1101/gr.1239303
- Chin CH, Chen SH, Wu HH, Ho CW, Ko MT,Lin CY. cytoHubba: identifying hub objects and sub-networks from complex interactome. BMC Systems Biol 2014; 8 (Suppl 4): S11. doi: 10.1186/1752-0509-8-s4-s11
- Gu Z, Gu L, Eils R, Schlesner M, Brors B. Circlize Implements and enhances circular visualization in R. Bioinformatics 2014; 30: 2811-2. doi: 10.1093/bioinformatics/btu393
- Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez JC, et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics 2011; 12: 77. doi: 10.1186/1471-2105-12-77
- Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, et al. Robust enumeration of cell subsets from tissue expression profiles. Nature Meth 2015; 12: 453-7. doi: 10.1038/nmeth.3337
- Chandrashekar DS, Karthikeyan SK, Korla PK, Patel H, Shovon AR, Athar M, et al. UALCAN: an update to the integrated cancer data analysis platform. Neoplasia 2022; 25: 18-27. doi: 10.1016/j.neo.2022.01.001
- Sjöstedt E, Zhong W, Fagerberg L, Karlsson M, Mitsios N, Adori C, et al. An atlas of the protein-coding genes in the human, pig, and mouse brain. Science 2020; 367: eaay5947. doi: 10.1126/science.aay5947
- Dekker E, Rex DK. Advances in CRC prevention: screening and surveillance. Gastroenterology 2018; 154: 1970-84. doi: 10.1053/j.gastro.2018.01.069
- Zhao P, Zhen H, Zhao H, Huang Y, Cao B. Identification of hub genes and potential molecular mechanisms related to radiotherapy sensitivity in rectal cancer based on multiple datasets. J Transl Med 2023; 21: 176. doi: 10.1186/s12967-023-04029-2
- Afshar S, Leili T, Amini P, Dinu I. Introducing novel key genes and transcription factors associated with rectal cancer response to chemoradiation through co-expression network analysis. Heliyon 2023; 9: e18869. doi: 10.1016/j.heliyon.2023.e18869
- Marinkovic M, Stojanovic-Rundic S, Stanojevic A, Ostojic M, Gavrilovic D, Jankovic R, et al. Exploring novel genetic and hematological predictors of response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer. Front genet 2023; 14: 1245594. doi: 10.3389/fgene.2023.1245594
- Nordlund P, Reichard P. Ribonucleotide reductases. Annu Rev Biochem 2006; 75: 681-706. doi: 10.1146/annurev.biochem.75.103004.142443
- Aye Y, Li M, Long MJ, Weiss RS. Ribonucleotide reductase and cancer: biological mechanisms and targeted therapies. Oncogene 2015; 34: 2011-21. doi: 10.1038/onc.2014.155
- Zhou S, Li J, Xu H, Zhang S, Chen X, Chen W, et al. Liposomal curcumin alters chemosensitivity of breast cancer cells to Adriamycin via regulating micro-RNA expression. Gene 2017; 622: 1-12. doi: 10.1016/j.gene.2017.04.026
- Itoi T, Sofuni A, Fukushima N, Itokawa F, Tsuchiya T, Kurihara T, et al. Ribonucleotide reductase subunit M2 mRNA expression in pretreatment biopsies obtained from unresectable pancreatic carcinomas. J Gastroenterol 2007; 42: 389-94. doi: 10.1007/s00535-007-2017-0
- Huang N, Guo W, Ren K, Li W, Jiang Y, Sun J, et al. LncRNA AFAP1-AS1 su-presses miR-139-5p and promotes cell proliferation and chemotherapy resistance of non-small cell lung cancer by competitively upregulating RRM2. Front Oncol 2019; 9: 1103. doi: 10.3389/fonc.2019.01103
- Lv D, Wu H, Xing R, Shu F, Lei B, Lei C, et al. HnRNP-L mediates bladder cancer progression by inhibiting apoptotic signaling and enhancing MAPK signaling pathways. Oncotarget 2017; 8: 13586-13599. doi: 10.18632/oncotarget.14600
- Yu X, Cao F, Yu Y, Li Y, Zhang J, Xu T, et al. HNRNPL Is identified and validated as a prognostic biomarker associated with microsatellite instability in human gastric cancer. DNA Cell Biol 2021; 40: 1251-60. doi: 10.1089/dna.2021.0165
- Zhao Y, Wang Y, Wang Q. HNRNPL affects the proliferation and apoptosis of colorectal cancer cells by regulating PD-L1. Pathol Res Pract 2021; 218: 153320. doi: 10.1016/j.prp.2020.153320
- Qiao L, Xie N, Bai Y, Li Y, Shi Y, Wang J, et al. Identification of upregulated HNRNPs associated with poor prognosis in pancreatic cancer. Biomed Res Int 2019; 2019: 5134050. doi: 10.1155/2019/5134050
- Müller J, Hart CM, Francis NJ, Vargas ML, Sengupta A, Wild B, et al. Histone methyltransferase activity of a Drosophila Polycomb group repressor complex. Cell 2002; 111: 197-208. doi: 10.1016/s0092-8674(02)00976-5
- Kodach LL, Jacobs RJ, Heijmans J, van Noesel CJ, Langers AM, Verspaget HW, et al. The role of EZH2 and DNA methylation in the silencing of the tumour suppressor RUNX3 in colorectal cancer. Carcinogenesis 2010; 31: 1567-75. doi: 10.1093/carcin/bgq147
- Bremer SCB, Conradi LC, Mechie NC, Amanzada A, Mavropoulou E, Kitz J, et al. Enhancer of zeste homolog 2 in colorectal cancer development and progression. Digestion 2021; 102: 227-35. doi: 10.1159/000504093
- Rehman AU, Iqbal MA, Sattar RSA, Saikia S, Kashif M, Ali WM, et al. Elevated expression of RUNX3 co-expressing with EZH2 in esophageal cancer patients from India. Cancer Cell Int 2020; 20: 445. doi: 10.1186/s12935-020-01534-y
- Heinze K, Rengsberger M, Gajda M, Jansen L, Osmers L, Oliveira-Ferrer L, et al. CAMK2N1/RUNX3 methylation is an independent prognostic biomarker for progression-free and overall survival of platinum-sensitive epithelial ovarian cancer patients. Clin Epigenetics 2021; 13: 15. doi: 10.1186/s13148-021-01006-8
- Wang C, Liu Z, Woo CW, Li Z, Wang L, Wei JS, et al. EZH2 Mediates epigenetic silencing of neuroblastoma suppressor genes CASZ1, CLU, RUNX3, and NGFR. Cancer Res 2012; 72: 315-24. doi: 10.1158/0008-5472.Can-11-0961
- Wang L, Wu X, Xu W, Gao L, Wang X, Li T. Combined detection of RUNX3 and EZH2 in evaluating efficacy of neoadjuvant therapy and prognostic value of middle and low locally advanced rectal cancer. Front Oncol 2022; 12: 713335. doi: 10.3389/fonc.2022.713335
- Alexandrov A, Martzen MR, Phizicky EM. Two proteins that form a complex are required for 7-methylguanosine modification of yeast tRNA. RNA 2002; 8: 1253-66. doi: 10.1017/s1355838202024019
- Pandolfini L, Barbieri I, Bannister AJ, Hendrick A, Andrews B, Webster N, et al. METTL1 promotes let-7 microRNA processing via m7G methylation. Mol Cell 2019; 74: 1278-90.e1279. doi: 10.1016/j.molcel.2019.03.040
- Tian QH, Zhang MF, Zeng JS, Luo RG, Wen Y, Chen J, et al. METTL1 overexpression is correlated with poor prognosis and promotes hepatocellular carcinoma via PTEN. J Mol Med 2019; 97: 1535-45. doi: 10.1007/s00109-019-01830-9
- Liu Y, Yang C, Zhao Y, Chi Q, Wang Z, Sun B. Overexpressed methyltransferase-like 1 (METTL1) increased chemosensitivity of colon cancer cells to cisplatin by regulating miR-149-3p/S100A4/p53 axis. Aging 2019; 11: 12328-344. doi: 10.18632/aging.102575
- Orellana EA, Liu Q, Yankova E, Pirouz M, De Braekeleer E, Zhang W, et al. METTL1-mediated m(7)G modification of Arg-TCT tRNA drives oncogenic transformation. Mol Cell 2021; 81: 3323-38.e3314. doi: 10.1016/j.molcel.2021.06.031
- Messiaen S, Guiard J, Aigueperse C, Fliniaux I, Tourpin S, Barroca V, et al. Loss of the histone chaperone ASF1B reduces female reproductive capacity in mice. Reproduction 2016; 151: 477-89. doi: 10.1530/rep-15-0327
- Zhang W, Gao Z, Guan M, Liu N, Meng F, Wang G. ASF1B promotes oncogenesis in lung adenocarcinoma and other cancer types. Front Oncol 2021; 11: 731547. doi: 10.3389/fonc.2021.731547
- Liu X, Song J, Zhang Y, Wang H, Sun H, Feng X, et al. ASF1B promotes cervical cancer progression through stabilization of CDK9. Cell Death Dis 2020; 11: 705. doi: 10.1038/s41419-020-02872-5
- Ouyang X, Lv L, Zhao Y, Zhang F, Hu Q, Li Z, et al. ASF1B serves as a potential therapeutic target by influencing cell cycle and proliferation in hepatocellular carcinoma. Front Oncol 2021; 11: 801506. doi: 10.3389/fonc.2021.801506
- Corpet A, De Koning L, Toedling J, Savignoni A, Berger F, Lemaître C, et al. Asf1b, the necessary Asf1 isoform for proliferation, is predictive of outcome in breast cancer. EMBO J 2011; 30: 480-93. doi: 10.1038/emboj.2010.335
- Qiu W, Wu X, Shi H, Liu B, Li L, Wu W, et al. ASF1B: A possible prognostic marker, therapeutic target, and predictor of immunotherapy in male thyroid carcinoma. Front Oncol 2022; 12: 678025. doi: 10.3389/fonc.2022.678025
- Yu GH, Gong XF, Peng YY, Qian J. Anti-silencing function 1B knockdown suppresses the malignant phenotype of colorectal cancer by inactivating the phosphatidylinositol 3-kinase/AKT pathway. World J Gastroint Oncol 2022; 14: 2353-66. doi: 10.4251/wjgo.v14.i12.2353
- Hu X, Zhu H, Zhang X, He X, Xu X. Comprehensive analysis of pan-cancer reveals potential of ASF1B as a prognostic and immunological biomarker. Cancer Med 2021; 10: 6897-916. doi: 10.1002/cam4.4203
- Zhang H, Han B, Han X, Zhu Y, Liu H, Wang Z, et al. Comprehensive analysis of splicing factor and alternative splicing event to construct subtypespecific prognosis-predicting models for breast cancer. Front Genet 2021; 12: 736423. doi: 10.3389/fgene.2021.736423
- Roerink SF, Sasaki N, Lee-Six H, Young MD, Alexandrov LB, Behjati S, et al. Intra-tumour diversification in colorectal cancer at the single-cell level. Nature 2018; 556: 457-62. doi: 10.1038/s41586-018-0024-3
- Pritchard CC, Cheng HH, Tewari M. MicroRNA profiling: approaches and considerations. Nat Rev Genet 2012; 13: 358-69. doi: 10.1038/nrg3198
- Hu JL, He GY, Lan XL, Zeng ZC, Guan J, Ding Y, et al. Inhibition of ATG12-mediated autophagy by miR-214 enhances radiosensitivity in colorectal cancer. Oncogenesis 2018; 7: 16. doi: 10.1038/s41389-018-0028-8